Atrial Fibrillation Clinical Trials

Find Atrial Fibrillation Clinical Trials Near You

Procedural Comparative Evaluation of Pulmonary Vein Isolation Using the FARAWAVE Nav PFA Catheter Without Pre-Ablation Computer Tomography (CT) vs. Conventional Farapulse With Pre-Ablation CT: A Single Centre Open-label, Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow. The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure. Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Atrial fibrillation (AF) documented on a 12-lead ECG, Holter monitor, or implantable cardiac device.

• Candidate for ablation according to current atrial fibrillation guidelines.

• Age ≥18 years at the time of informed consent.

• Signed informed consent obtained

Locations
Other Locations
Switzerland
Cardiocentro Ticino - Ente Ospedaliero Cantonale
RECRUITING
Lugano
Contact Information
Primary
Marco Bergonti, MD PhD
bergmar21@gmail.com
+41 (0) 91 811 51 11
Time Frame
Start Date: 2025-11-10
Estimated Completion Date: 2026-12
Participants
Target number of participants: 58
Treatments
Experimental: Intervention
FARAWAVE Nav without pre-ablation CT
Active_comparator: Control
FARAPULSE with pre-ablation CT
Related Therapeutic Areas
Sponsors
Leads: Cardiocentro Ticino

This content was sourced from clinicaltrials.gov